Defunct Company
Total Trials
9
As Lead Sponsor
7
As Collaborator
2
Total Enrollment
618
NCT01596920
Grafix® DFU: Open-Label Extension Option to Evaluate Safety & Efficacy of Grafix® for Chronic Diabetic Foot Ulcers
Phase: Phase 4
Role: Lead Sponsor
Start: Apr 30, 2012
Completion: Mar 31, 2014
NCT02260609
GrafixCORE®: Open-Label Study to Evaluate the Safety and Efficacy of GrafixCORE® for Complex Diabetic Foot Wounds
Start: Oct 31, 2014
Completion: Not specified
NCT02571738
Study to Evaluate the Safety and Efficacy of CHAM* for the Treatment of Diabetic Foot Ulcers
Phase: Phase 3
Start: Oct 31, 2015
Completion: Jun 30, 2017
NCT02675855
GrafixPRIME® for the Treatment of Chronic Diabetic Foot Ulcers
Start: Jan 31, 2016
Completion: Jul 31, 2017
NCT02936115
TruSkin®: Study for the Treatment of Chronic Diabetic Foot Ulcers
Start: Jul 31, 2016
Completion: Apr 30, 2017
NCT02936128
TruSkin®: Study for Treatment of Chronic Venous Leg Ulcers
NCT03629236
Study to Evaluate Safety and Efficacy of GrafixPL for the Treatment of Venous Leg Ulcers
Phase: N/A
Start: Jun 27, 2018
Completion: Jun 24, 2021
NCT03742440
GrafixPL PRIME Evaluation Case Study
Role: Collaborator
Start: Nov 20, 2018
Completion: Mar 1, 2020
NCT04405765
Cryopreserved vs. Lyopreserved Stravix as an Adjunct to NPWT in the Treatment of Complex Wounds
Start: Jun 22, 2021
Completion: Jul 7, 2022